N-[(E)-1-(1H-benzimidazol-2-yl)-2-(pyridin-3-yl)ethenyl]-3-bromobenzamide

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-[(E)-1-(1H-benzimidazol-2-yl)-2-(pyridin-3-yl)ethenyl]-3-bromobenzamide
• 英文别名: N-[(E)-1-(1H-benzimidazol-2-yl)-2-pyridin-3-ylethenyl]-3-bromobenzamide
• 化学式: C₂₁H₁₅BrN₄O
• 分子量: 419.3
• InChiKey: GEKWYGVEXDUQMM-YBFXNURJSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4
• 重原子数：
  27
• 可旋转键数：
  4
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  70.7
• 氢给体数：
  2
• 氢受体数：
  3

文献信息

• TARGETING LASP1, EIF4A1, EIF4B AND CXC4 WITH MODULATORS AND COMBINATIONS THEREOF FOR CANCER THERAPY
  申请人：The University of Toledo

  公开号：US20220151976A1

  公开（公告）日：2022-05-19

  Described herein are compositions, formulations, and methods useful for sensitizing cancer cells to chemotherapeutic agents, for inhibiting expression or translation of oncogenic proteins, for inhibiting eIF4A, for inhibiting c-MYC, for reducing sternness of breast cancer cells, for treating breast cancer, for overcoming drug resistance of drug-resistant cancer cells, and for reducing tumor cell viability, involving one or more inhibitors of eIF4A, LASP1, CXCR4, CXCL8, CXCL12, ROCK1, BIRC5, MDM2, CCND1, and c-MYC.